Technology | September 08, 2014

iCAD Expands Partnership With Volpara Solutions to Offer Enhanced Breast Imaging Analytics for 2-D Mammography and Tomosynthesis

New additions to PowerLook AMP provide radiologists a consistent, standardized way to evaluate performance of breast imaging systems in real time

September 8, 2014 — iCAD Inc. announced that, in addition to Volpara Density volumetric breast density assessment software, Volpara Analytics and Volpara Dose solutions are now available as part of iCAD’s PowerLook Advanced Mammography Platform (AMP). With the addition of these quantitative breast-imaging tools, radiologists will be able to evaluate the performance of all major digital mammography and tomosynthesis units and obtain patient-specific dose information to make informed treatment decisions in real time.

“Today’s healthcare environment is increasingly data-driven and our customers require up-to-the-minute access to analytics that impact patient care,” said Ken Ferry, CEO of iCAD. “By incorporating additional breast imaging analytic and reporting solutions from Volpara, our PowerLook AMP customers will be able to go beyond automated mammography unit settings and mine patient-specific, real-time information for actionable insights regarding care delivery within their practices and across patient populations.”

PowerLook AMP is a next-generation digital mammography computer-aided detection (CAD) platform that provides radiologists with the ability to customize their 2-D CAD solution to meet the needs of their individual work environment. Now with the option to incorporate VolparaAnalytics and VolparaDose in addition to VolparaDensity, PowerLook AMP users will, among other benefits, be able to:

  • Improve patient safety and reporting through personalized measurements of density, patient dose, breast compression and other volumetric factors designed to help maintain accuracy and consistent quality in breast screening.
  • Optimize performance/utilization of staff and mammography systems.
  • Utilize a globally-accepted algorithm incorporating breast density to generate patient-specific radiation dose estimates, which can be automatically entered in patient communications.

Cleared by the U.S. Food and Drug Administration (FDA), HealthCanada, the TGA and CE-marked, VolparaDensity is used by radiologists to objectively assess density from both digital mammography and tomosynthesis images to help doctors evaluate who might benefit from additional screening. Highly correlated to breast magnetic resonance imaging (MR) assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the ACR (American College of Radiology) breast density categories. To date, more than 3 million women have had their breast density analyzed using VolparaDensity.

For more information:

Related Content Debuts  Spanish Language Video  About Dense Breasts
News | Breast Density | September 12, 2017
Breast cancer risks associated with breast density are the subject of a new Spanish language video launched recently by...
Asian Study Underlines Potential Value of Pressure-Guided Mammography
News | Mammography | September 11, 2017
Sigmascreening recently announced that a study of in total 15,898 in digital mammograms from 3,772 Asian women...
Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project
News | Ultrasound Womens Healthcare | September 08, 2017
September 8, 2017 — Delphinus Medical Technologies Inc.
Patient X-ray radiation exposure from medical imaging has been a hot topic in radiology and has prompted the implementation of radiation dose monitoring systems.
Feature | Radiation Dose Management | September 08, 2017 | By Dave Fornell
Patient X-ray radiation exposure from medical imaging has been a hot topic in radiology and has prompted the...
Technology | Radiation Dose Management | September 07, 2017
September 7, 2017 — Sapheneia and Scannerside received U.S.
FDA Clears Senographe Pristina Mammography System With Patient-Assisted Compression
Technology | Mammography | September 05, 2017
The U.S. Food and Drug Administration (FDA) cleared GE Healthcare’s Senographe Pristina with Self-Compression, the...
FDA Releases Six-Month Inspection Data From EQUIP Mammography Quality Initiative
News | Mammography | September 01, 2017
September 1, 2017 — The Division of Mammography Quality Standards (DMQS) of the U.S.
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
Comparison of Screening Recommendations Supports Annual Mammography. Marilyn Fornell
News | Mammography | August 22, 2017
When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue...
Overlay Init